These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34615406)

  • 1. One-year outcome of cystoid macular degeneration in central serous chorioretinopathy.
    Kumar Sahoo N; Lupidi M; Goud A; Gangakhedkar S; Cardillo Piccolino F; Chhablani J
    Eur J Ophthalmol; 2022 Jul; 32(4):2347-2354. PubMed ID: 34615406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy.
    Rabiolo A; Zucchiatti I; Marchese A; Baldin G; Sacconi R; Montorio D; Cicinelli MV; Querques L; Bandello F; Querques G;
    Eye (Lond); 2018 Jan; 32(1):55-66. PubMed ID: 29265111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optical coherence tomography angiography findings in cystoid macular degeneration associated with central serous chorioretinopathy.
    Sahoo NK; Mishra SB; Iovino C; Singh SR; Munk MR; Berger L; Peiretti E; Chhablani J
    Br J Ophthalmol; 2019 Nov; 103(11):1615-1618. PubMed ID: 30602447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
    van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical feature of cystoid macular degeneration in central serous chorioretinopathy.
    Gorhe S; Chugh MK; Goel N; D'Souza Z; Saurabh K; Roy R
    Indian J Ophthalmol; 2023 Nov; 71(11):3489-3493. PubMed ID: 37870012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
    Nicolò M; Zoli D; Musolino M; Traverso CE
    Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3.
    Feenstra HMA; van Dijk EHC; van Rijssen TJ; Tsonaka R; Diederen RMH; Hoyng CB; Schlingemann RO; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2023 Mar; 261(3):659-668. PubMed ID: 36202933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choroidal Anatomic Alterations After Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: A Multicenter Study.
    Iovino C; Au A; Chhablani J; Parameswarappa DC; Rasheed MA; Cennamo G; Cennamo G; Montorio D; Ho AC; Xu D; Querques G; Borrelli E; Sacconi R; Pichi F; Woodstock E; Sadda SR; Corradetti G; Boon CJF; van Dijk EHC; Loewenstein A; Zur D; Yoshimi S; Freund KB; Peiretti E; Sarraf D
    Am J Ophthalmol; 2020 Sep; 217():104-113. PubMed ID: 32360342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of half-fluence photodynamic therapy and eplerenone in chronic central serous chorioretinopathy: A comparative study.
    Manayath G; Verghese S; Ranjan R; Agrawal H; Khanna A; Narendran V; Chhablani J
    Eur J Ophthalmol; 2021 Nov; 31(6):3110-3116. PubMed ID: 33508971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One year outcome and predictors of treatment outcome in central serous chorioretinopathy: Multimodal imaging based analysis.
    Arora S; Maltsev DS; Singh Randhir S; Sahoo NK; Jhingan M; Parmeshwarappa D; Arora T; Kulikov A; Iovino C; Zur D; Fainberg G; Ibrahim MN; Tatti F; Gujar R; Venkatesh R; Reddy N; Snehith R; Peiretti E; Lupidi M; Chhablani J
    Eur J Ophthalmol; 2022 Jul; 32(4):2319-2327. PubMed ID: 34747194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the changes in choroidal macular anastomoses after photodynamic therapy and in the follow-up of central serous chorioretinopathy by en face optical coherence tomography.
    Oribio-Quinto C; Alarcón-García AD; Fuentes JE; Fernández-Vigo JI
    Photodiagnosis Photodyn Ther; 2023 Sep; 43():103719. PubMed ID: 37487812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. INSTRUMENTAL DIFFERENCE IN ASSESSING CHOROIDAL HYPERPERMEABILITY AND PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Lee SM; Kwon HJ; Park SW; Lee JE; Byon IS
    Retina; 2019 Jul; 39(7):1361-1369. PubMed ID: 29554076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular and structural alterations of the choroid evaluated by optical coherence tomography angiography and optical coherence tomography after half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Demirel S; Özcan G; Yanık Ö; Batıoğlu F; Özmert E
    Graefes Arch Clin Exp Ophthalmol; 2019 May; 257(5):905-912. PubMed ID: 30617579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Eplerenone in Chronic Central Serous Chorioretinopathy Refractory to Photodynamic Therapy.
    Karagiannis D; Parikakis E; Kontomichos L; Batsos G; Chatziralli I
    Semin Ophthalmol; 2019; 34(6):436-441. PubMed ID: 31309849
    [No Abstract]   [Full Text] [Related]  

  • 15. CLINICAL FEATURES OF FLAT IRREGULAR PIGMENT EPITHELIAL DETACHMENT ASSOCIATED WITH CHOROIDAL NEOVASCULARIZATION IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Guo J; Tang W; Liu W; Chang Q; Xu G
    Retina; 2021 Jan; 41(1):199-207. PubMed ID: 32251241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Son BK; Kim K; Kim ES; Yu SY
    Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser.
    van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; Keunen JEE; MacLaren RE; Hoyng CB; Downes SM; Fauser S; Boon CJF
    Acta Ophthalmol; 2021 Nov; 99(7):805-811. PubMed ID: 33565230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy.
    Gawęcki M; Jaszczuk-Maciejewska A; Jurska-Jaśko A; Kneba M; Grzybowski A
    BMC Ophthalmol; 2019 Jul; 19(1):160. PubMed ID: 31345183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and treatment responses of cystoid retina associated with central serous chorioretinopathy.
    Fukuyama H; Komuku Y; Gomi F
    Jpn J Ophthalmol; 2021 May; 65(3):372-379. PubMed ID: 33532933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macular ganglion cell complex thickness in acute and chronic central serous chorioretinopathy.
    Demirok G; Kocamaz F; Topalak Y; Altay Y; Sengun A
    Int Ophthalmol; 2017 Apr; 37(2):409-416. PubMed ID: 27324370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.